Hier zaten we toch op te wachten? (delen uit de conclusie van het Anderson onderzoek terzake haar "diepvries" allogene NK/ CD19 onderzoek):
Responses were durable, with a 70% probability of remaining in CR at 1 year for those patients achieving early remission. Similar results have been reported for patients with lymphoid malignancies receiving autologous CAR19 T cells38,43.
The use of allogeneic immune cells from healthy donors offers several advantages over autologous patient-derived cells including generation of multiple therapeutic cell doses from a single donor that could be cryopreserved for off-the-shelf use, making the allogeneic products cost effective, readily available and with the potential for a consistent and high-quality treatment.
Notably, higher NK cell cytotoxicity was associated with reduced cancer risk, while lower activity was associated with increased risk47.
In our study, donor-related factors such as the NRBC content and the time from collection to cryopreservation were the main predictors for outcome, defining the concept of the optimal CBU. This stresses the importance of identifying donor-specific predictors of response after allogeneic cell therapy, especially since one donor may be used to treat hundreds if not thousands of patients.
In conclusion, we show that CAR19/IL-15 CBU-NK cells have a similar efficacy profile to autologous CAR19 T cells. The safety profile, however, is very different as CAR19/IL-15 CBU-NK cells are not associated with notable CRS or neurotoxicity. Moreover, our findings underscore the importance of defining the criteria for the selection of an allogeneic donor for CAR-NK cell production and identifying donor-specific predictors of response.
Ondernemingen die nu nog zwaar investeren in CAR-t (Galapagos) zitten volgens mij aan een dood paard te trekken. Affimed heeft m.i. bewezen dat haar ICE's net zo goed en veelzijdig zijn dan CAR-NK. Top!